Literature DB >> 33546852

Multiple hepatocellular carcinoma: Long-term outcomes following resection beyond actual guidelines. An Italian multicentric retrospective study.

Ilenia Bartolini1, Tommaso Nelli2, Nadia Russolillo3, Alessandro Cucchetti4, Benedetta Pesi2, Luca Moraldi5, Alessandro Ferrero3, Giorgio Ercolani4, Gianluca Grazi6, Giacomo Batignani2.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is frequently diagnosed as multinodular. This study aims to assess prognostic factors for survival and identify patients with multiple HCC who may benefit from surgery beyond the Barcelona Clinic Liver Cancer classification indications.
METHODS: This retrospective study included all the consecutive patients from 4 Italian tertiary centers receiving liver resection for naive multiple HCC between 1990 and 2012 to have a potential follow-up of 5 years.
RESULTS: Included patients were 144. Ninety-day morbidity and mortality rates were 38.3% and 8.3%, respectively. The 5-year overall and disease-free survival rates were 33.3% and 19.1%, respectively. Tumor size <3 cm, bilirubin, Child-Pugh A, BCLC-A stage, being within "up-to-7" criteria, and minor resections resulted in prognostic factors. The Child-Pugh score resulted in an independent prognostic factor.
CONCLUSIONS: Surgery may be related to good outcomes in selected patients with multiple HCC.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Guidelines; Liver resection; Liver surgery indication; Multiple HCC; Prognostic factors

Year:  2021        PMID: 33546852     DOI: 10.1016/j.amjsurg.2021.01.023

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis.

Authors:  Matteo Risaliti; Ilenia Bartolini; Claudia Campani; Umberto Arena; Carlotta Xodo; Valentina Adotti; Martina Rosi; Antonio Taddei; Paolo Muiesan; Amedeo Amedei; Giacomo Batignani; Fabio Marra
Journal:  World J Gastroenterol       Date:  2022-08-07       Impact factor: 5.374

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.